Objective
We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition. Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization. In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.
Fields of science
Keywords
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
UNIVERSITAETSKLINIKUM FREIBURG
Net EU contribution
€ 150 000,00
Address
HUGSTETTER STRASSE 49
79106 Freiburg
Germany
79106 Freiburg
Germany
Region
Baden-Württemberg
Freiburg
Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data